NO930731L - Kininogenaseinhibitorer - Google Patents

Kininogenaseinhibitorer

Info

Publication number
NO930731L
NO930731L NO93930731A NO930731A NO930731L NO 930731 L NO930731 L NO 930731L NO 93930731 A NO93930731 A NO 93930731A NO 930731 A NO930731 A NO 930731A NO 930731 L NO930731 L NO 930731L
Authority
NO
Norway
Prior art keywords
amino acid
group
analog
amide
conformational
Prior art date
Application number
NO93930731A
Other languages
English (en)
Other versions
NO930731D0 (no
Inventor
Michael Szelke
David Michael Evans
David Michael Jones
Original Assignee
Ferring Peptide Research Partn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Peptide Research Partn filed Critical Ferring Peptide Research Partn
Publication of NO930731D0 publication Critical patent/NO930731D0/no
Publication of NO930731L publication Critical patent/NO930731L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0227—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06 - C07K5/10

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Kininogenaseinhibitorer, som optimalt ikke overskrider størrelsen av et heksapeptid, represen-tert ved (II), hvor A og B = aminoacyl (omfattende aminoacylanalog) som er de samme eller forskjellige og danner en dipeptidgruppe hvor aminosyren A "har en terminalgruppe og er en hvilken som helst amino- eller iminosyrerest (men fortrinnsvis med D-konfigurasjon, og B er en lipofil aminosyrerest med D- eller L-konfigurasjon, men ikke prolin eller en prolinanalog, eller en konformasjonsanalog av nevnte dipeptidgruppe hvor peptidbindingen er erstattet med -CH-NH- ("redusert"), -CH(OH)-CH- ("hydroksy"), -CO-CH("keto"), -CHCH- ("hydrokarbon") eller en annen konformasjonsetterligning av peptidbindingen og i (III) skal sidekjeden Rvære sidekjeden i en basisk aminosyre eller aminosyreanalog (fortrinnsvis med L-konfigurasjon), og R være H eller lavere alkyl(0-0) eller C eller peptidbindingen omfattende -N(R)- er erstattet, hvilket farer til en konformasjonsetterligning som ovenfor; V = en bindingsøkende eller karbonylaktiverende gruppe, fortrinnsvis valgt fra H (når A eller B må være cykloheksylalanin, fortrinnsvis D dersom den er A eller L dersom den er B) eller alkyl (CCq) eller fluoralkyl (C-C); substituert oksymetylen; tiometylen; sulfoksymetylen; sulfonylmetylen; aminometylen; hydrazino-metylen; -CH-Het (hvor Het = en substituert eller usubstituert heterocyklus); substituert amino (men når den resulterende forbindelse er et sekundært alkylamid, må B ikke være fenylalanin); en aminosyregruppe eller dens ester eller amid; et karboksylisk sekundært amid eller primært amid, når B må være cykloheksylalanin eller adamantylalanin eller en annen svær lipofil, ikke-aromatisk aminosyre (ikke Ala Leu Ile Val Nva Met Nie Phe Tyr Trp Nal (1)); tertiært karboksamid; karboksyalkylgruppe eller dens ester eller amid eller aminoacylderivat.
NO93930731A 1990-09-07 1993-02-26 Kininogenaseinhibitorer NO930731L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909019558A GB9019558D0 (en) 1990-09-07 1990-09-07 Enzyme inhibitors
PCT/GB1991/001479 WO1992004371A1 (en) 1990-09-07 1991-09-02 Kininogenase inhibitors

Publications (2)

Publication Number Publication Date
NO930731D0 NO930731D0 (no) 1993-02-26
NO930731L true NO930731L (no) 1993-05-07

Family

ID=10681831

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93930731A NO930731L (no) 1990-09-07 1993-02-26 Kininogenaseinhibitorer

Country Status (13)

Country Link
EP (1) EP0652893A1 (no)
JP (1) JPH06501461A (no)
AU (1) AU8438791A (no)
CA (1) CA2090858A1 (no)
FI (1) FI930946A (no)
GB (1) GB9019558D0 (no)
HU (1) HUT64084A (no)
IE (1) IE913120A1 (no)
MC (1) MC2313A1 (no)
NO (1) NO930731L (no)
PT (1) PT98885A (no)
WO (1) WO1992004371A1 (no)
ZA (1) ZA917096B (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103612D0 (sv) * 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
US5374623A (en) * 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use
US6984627B1 (en) 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
SE9301911D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5783563A (en) * 1993-06-03 1998-07-21 Astra Aktiebolag Method for treatment or prophylaxis of venous thrombosis
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
GB9318637D0 (en) * 1993-09-08 1993-10-27 Ferring Res Ltd Enzyme inhibitors
US5486623A (en) 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
US6025472A (en) * 1994-12-21 2000-02-15 Corvas International, Inc. N-substituted glycine derivatives as enzyme inhibitors
US5696231A (en) * 1994-12-21 1997-12-09 Corvas International, Inc. N-substituted glycine derivatives as enzyme inhibitors
US6586466B2 (en) 1995-10-30 2003-07-01 Smithkline Beecham Corporation Carbohydrazide-protease inhibitors
SK56798A3 (en) 1995-10-30 1998-12-02 Smithkline Beecham Corp Protease inhibitors, pharmaceutical composition containing them and their use
TW541316B (en) * 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
IL139162A0 (en) 1998-04-24 2001-11-25 Dimensional Pharm Inc Amidinohydrazone, alkoxyguanidine and aminoguanidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
YU42401A (sh) 1998-12-14 2003-12-31 Ortho-Mcneil Pharmaceuticals Inc. Supstituisani heterociklični acil-tripeptidi korisni kao modulatori receptora trombina
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
EP1158996A4 (en) 1999-02-18 2005-01-12 Kaken Pharma Co Ltd NEW AMID DERIVATIVES AS GROWTH HORMONE SECRETION CONVEYORS
WO2001034599A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
JP2003513972A (ja) 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
US6534498B1 (en) 1999-11-10 2003-03-18 Smithkline Beecham Corporation Protease inhibitors
EA005893B1 (ru) 2000-03-21 2005-06-30 Смитклайн Бичам Корпорейшн Ингибиторы протеаз
GB0205527D0 (en) * 2002-03-08 2002-04-24 Ferring Bv Inhibitors
CA2491611A1 (en) 2002-07-03 2004-01-15 Bio Science International, Inc. Peptides comprising aromatic d-amino acids and methods of use
FR2846969A1 (fr) * 2002-11-08 2004-05-14 Salles Jean Pierre Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical
EP1736465A4 (en) * 2004-03-31 2009-06-17 Ajinomoto Kk ANILINE DERIVATIVES
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
IL239682B (en) 2013-01-08 2018-10-31 Kalvista Pharmaceuticals Ltd History of benzylamine and 2-(aminomethyl)pyridine
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
MX363689B (es) 2013-05-23 2019-03-29 Kalvista Pharmaceuticals Ltd Derivados de heterociclicos.
MX366498B (es) 2013-08-14 2019-07-11 Kalvista Pharmaceuticals Ltd Inhibidores de calicreina plasmatica.
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
EP3204352B1 (en) 2014-10-06 2020-07-01 Cortexyme, Inc. Inhibitors of lysine gingipain
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
CA3004095A1 (en) 2015-11-09 2017-05-18 Cortexyme, Inc. Inhibitors of arginine gingipain
RU2020140891A (ru) 2016-05-31 2021-02-10 Калвиста Фармасьютикалз Лимитед Производные пиразола в качестве ингибиторов калликреина
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
WO2018053353A1 (en) 2016-09-16 2018-03-22 Cortexyme, Inc. Ketone inhibitors of lysine gingipain
CN107043338B (zh) * 2017-03-24 2018-09-25 东华大学 一类5-氨基酮戊酸衍生物及其制备方法和应用
CN107011217B (zh) * 2017-03-24 2018-08-14 东华大学 一类脂溶性5-氨基酮戊酸衍生物及其制备方法和应用
IL274557B1 (en) 2017-11-29 2024-05-01 Kalvista Pharmaceuticals Ltd Dosage forms containing a plasma kallikrein inhibitor
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
GB201910125D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
GB201918994D0 (en) 2019-12-20 2020-02-05 Kalvista Pharmaceuticals Ltd Treatments of diabetic macular edema and impaired visual acuity
GB2591730A (en) 2019-12-09 2021-08-11 Kalvista Pharmaceuticals Ltd New polymorphs
TW202228686A (zh) 2020-10-15 2022-08-01 英商卡爾維斯塔製藥有限公司 血管性水腫之治療
EP4232031A1 (en) 2020-10-23 2023-08-30 Kalvista Pharmaceuticals Limited Treatments of angioedema
WO2022172006A1 (en) 2021-02-09 2022-08-18 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023002219A1 (en) 2021-07-23 2023-01-26 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
EP4288036A1 (en) 2022-04-27 2023-12-13 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0009010B1 (en) * 1978-07-18 1983-03-02 Kabi AB Bradykinin inhibiting tripeptide derivatives, process for their preparation and pharmaceutical preparations containing them
US4563305A (en) * 1981-01-07 1986-01-07 University Of Miami Radiolabelled substrates for assaying mammalian enzymes
US4835253A (en) * 1987-04-03 1989-05-30 The University Hospital Specific inhibitors of tissue kallikrein
ZA897514B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors

Also Published As

Publication number Publication date
GB9019558D0 (en) 1990-10-24
FI930946A0 (fi) 1993-03-03
CA2090858A1 (en) 1992-03-08
PT98885A (pt) 1992-08-31
MC2313A1 (fr) 1993-09-27
AU8438791A (en) 1992-03-30
IE913120A1 (en) 1992-03-11
ZA917096B (en) 1992-04-29
HU9300610D0 (en) 1993-05-28
HUT64084A (en) 1993-11-29
WO1992004371A1 (en) 1992-03-19
FI930946A (fi) 1993-04-26
NO930731D0 (no) 1993-02-26
EP0652893A1 (en) 1995-05-17
JPH06501461A (ja) 1994-02-17

Similar Documents

Publication Publication Date Title
NO930731L (no) Kininogenaseinhibitorer
GB1586521A (en) Analgesic tetrapeptides and pentapeptides
US5484771A (en) Antiherpes peptide derivatives having a 1,4-dioxo-C, N-terminus
Ondetti Citrulline-containing analogs of bradykinin
US4439360A (en) Retro-inverso analogues of C-terminal penta and hexapeptides of Substance P
AU5963290A (en) Inhibition of the n-end rule pathway in living cells
US4638046A (en) Retro-inverso C-terminal hexapeptide analogues of substance P
WO1992017025A3 (en) GnRH analogs
US4104371A (en) Psychopharmacologically active peptides and peptide-derivatives, and the use thereof
SG171348A1 (en) Tumor necrosis factor alpha inhibiting peptides and uses thereof
GB1584968A (en) Pentapeptides processes for their preparation and pharmaceutical compositions containing them
Jarvis et al. Structure of the cell wall of Staphylococcus aureus. VIII. Structure and chemical synthesis of the basic peptides released by the Myxobacterium enzyme
US5312811A (en) Peptide derivatives and antidemetia agents
HU190915B (en) Process for preparing new tripeptide derivatives
US4111923A (en) Octapeptides and methods for their production
Sugano et al. Studies of peptide antibiotics. XXX. Syntheses of gramicidin S analogs containing N-methylleucine in place of leucine
GB1587427A (en) Polypeptide derivatives
KR920701180A (ko) 4h-3,1-벤즈옥사진-4-온 화합물 및 그의 엘라스타아제 저해용 약학조성물
Boger Renin inhibitors. Design of angiotensinogen transition-state analogs containing statine
US4087419A (en) Heptapeptides and methods for their production
Byk et al. Synthesis and conformational analysis of peptide inhibitors of farnesyltransferase
HU181402B (en) Process for preparing new peptides with psychopharmacological activity
SALVADORI et al. Synthesis and Opioid Activity of [Sar 4] Dermorphin-Tetrapeptide Analogues
RU2442791C1 (ru) Способ получения бусерелина и промежуточные соединения для его получения
US4271152A (en) Psycho-pharmacological peptides